Updates on radiotherapy-immunotherapy combinations: Proceedings of 6th annual ImmunoRad conference

Fabiana Gregucci; Sheila Spada; Mary Helen Barcellos-Hoff; Nina Bhardwaj; Charleen Chan Wah Hak; Alba Fiorentino; Chandan Guha; Monica L. Guzman; Kevin Harrington; Fernanda G. Herrera; Jamie Honeychurch; Theodore Hong; Lorea Iturri; Elisabeth Jaffee; Sana D. Karam; Simon R.V. Knott; Constantinos Koumenis; David Lyden; Ariel E. Marciscano; Alan Melcher; Michele Mondini; Anna Mondino; Zachary S. Morris; Sean Pitroda; Sergio A. Quezada; Laura Santambrogio; Stephen Shiao; John Stagg; Irma Telarovic; Robert Timmerman; Marie Catherine Vozenin; Ralph Weichselbaum; James Welsh; Anna Wilkins; Chris Xu; Roberta Zappasodi; Weiping Zou; Alexandre Bobard; Sandra Demaria; Lorenzo Galluzzi; Eric Deutsch; Silvia C. Formenti

doi:10.1080/2162402X.2023.2222560

Updates on radiotherapy-immunotherapy combinations: Proceedings of 6^th annual ImmunoRad conference

Fabiana Gregucci, Sheila Spada, Mary Helen Barcellos-Hoff, Nina Bhardwaj, Charleen Chan Wah Hak, Alba Fiorentino, Chandan Guha, Monica L. Guzman, Kevin Harrington, Fernanda G. Herrera, Jamie Honeychurch, Theodore Hong, Lorea Iturri, Elisabeth Jaffee, Sana D. Karam, Simon R.V. Knott, Constantinos Koumenis, David Lyden, Ariel E. Marciscano, Alan MelcherMichele Mondini, Anna Mondino, Zachary S. Morris, Sean Pitroda, Sergio A. Quezada, Laura Santambrogio, Stephen Shiao, John Stagg, Irma Telarovic, Robert Timmerman, Marie Catherine Vozenin, Ralph Weichselbaum, James Welsh, Anna Wilkins, Chris Xu, Roberta Zappasodi, Weiping Zou, Alexandre Bobard, Sandra Demaria, Lorenzo Galluzzi, Eric Deutsch, Silvia C. Formenti

Résultats de recherche: Contribution à un journal › Article 'review' › Revue par des pairs

7 Citations (Scopus)

Résumé

Focal radiation therapy (RT) has attracted considerable attention as a combinatorial partner for immunotherapy (IT), largely reflecting a well-defined, predictable safety profile and at least some potential for immunostimulation. However, only a few RT-IT combinations have been tested successfully in patients with cancer, highlighting the urgent need for an improved understanding of the interaction between RT and IT in both preclinical and clinical scenarios. Every year since 2016, ImmunoRad gathers experts working at the interface between RT and IT to provide a forum for education and discussion, with the ultimate goal of fostering progress in the field at both preclinical and clinical levels. Here, we summarize the key concepts and findings presented at the Sixth Annual ImmunoRad conference.

langue originale	Anglais
Numéro d'article	2222560
journal	OncoImmunology
Volume	12
Numéro de publication	1
Les DOIs	https://doi.org/10.1080/2162402X.2023.2222560
état	Publié - 1 janv. 2023

Accès au document

10.1080/2162402X.2023.2222560

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

Gregucci, F., Spada, S., Barcellos-Hoff, M. H., Bhardwaj, N., Chan Wah Hak, C., Fiorentino, A., Guha, C., Guzman, M. L., Harrington, K., Herrera, F. G., Honeychurch, J., Hong, T., Iturri, L., Jaffee, E., Karam, S. D., Knott, S. R. V., Koumenis, C., Lyden, D., Marciscano, A. E., ... Formenti, S. C. (2023). Updates on radiotherapy-immunotherapy combinations: Proceedings of 6^th annual ImmunoRad conference. OncoImmunology, 12(1), Article 2222560. https://doi.org/10.1080/2162402X.2023.2222560

@article{ab2a78b661ea48f29a0bc39e65427ea9,

title = "Updates on radiotherapy-immunotherapy combinations: Proceedings of 6th annual ImmunoRad conference",

abstract = "Focal radiation therapy (RT) has attracted considerable attention as a combinatorial partner for immunotherapy (IT), largely reflecting a well-defined, predictable safety profile and at least some potential for immunostimulation. However, only a few RT-IT combinations have been tested successfully in patients with cancer, highlighting the urgent need for an improved understanding of the interaction between RT and IT in both preclinical and clinical scenarios. Every year since 2016, ImmunoRad gathers experts working at the interface between RT and IT to provide a forum for education and discussion, with the ultimate goal of fostering progress in the field at both preclinical and clinical levels. Here, we summarize the key concepts and findings presented at the Sixth Annual ImmunoRad conference.",

keywords = "FLASH radiotherapy, dose and fractionation, immune checkpoint inhibitors, immunomodulators, lymph node sparing, tumor-associated macrophages",

author = "Fabiana Gregucci and Sheila Spada and Barcellos-Hoff, {Mary Helen} and Nina Bhardwaj and {Chan Wah Hak}, Charleen and Alba Fiorentino and Chandan Guha and Guzman, {Monica L.} and Kevin Harrington and Herrera, {Fernanda G.} and Jamie Honeychurch and Theodore Hong and Lorea Iturri and Elisabeth Jaffee and Karam, {Sana D.} and Knott, {Simon R.V.} and Constantinos Koumenis and David Lyden and Marciscano, {Ariel E.} and Alan Melcher and Michele Mondini and Anna Mondino and Morris, {Zachary S.} and Sean Pitroda and Quezada, {Sergio A.} and Laura Santambrogio and Stephen Shiao and John Stagg and Irma Telarovic and Robert Timmerman and Vozenin, {Marie Catherine} and Ralph Weichselbaum and James Welsh and Anna Wilkins and Chris Xu and Roberta Zappasodi and Weiping Zou and Alexandre Bobard and Sandra Demaria and Lorenzo Galluzzi and Eric Deutsch and Formenti, {Silvia C.}",

note = "Publisher Copyright: {\textcopyright} 2023 The Author(s). Published with license by Taylor & Francis Group, LLC.",

year = "2023",

month = jan,

day = "1",

doi = "10.1080/2162402X.2023.2222560",

language = "English",

volume = "12",

journal = "OncoImmunology",

issn = "2162-4011",

number = "1",

}

Gregucci, F, Spada, S, Barcellos-Hoff, MH, Bhardwaj, N, Chan Wah Hak, C, Fiorentino, A, Guha, C, Guzman, ML, Harrington, K, Herrera, FG, Honeychurch, J, Hong, T, Iturri, L, Jaffee, E, Karam, SD, Knott, SRV, Koumenis, C, Lyden, D, Marciscano, AE, Melcher, A, Mondini, M, Mondino, A, Morris, ZS, Pitroda, S, Quezada, SA, Santambrogio, L, Shiao, S, Stagg, J, Telarovic, I, Timmerman, R, Vozenin, MC, Weichselbaum, R, Welsh, J, Wilkins, A, Xu, C, Zappasodi, R, Zou, W, Bobard, A, Demaria, S, Galluzzi, L, Deutsch, E & Formenti, SC 2023, 'Updates on radiotherapy-immunotherapy combinations: Proceedings of 6^th annual ImmunoRad conference', OncoImmunology, VOL. 12, Numéro 1, 2222560. https://doi.org/10.1080/2162402X.2023.2222560

TY - JOUR

T1 - Updates on radiotherapy-immunotherapy combinations

T2 - Proceedings of 6th annual ImmunoRad conference

AU - Gregucci, Fabiana

AU - Spada, Sheila

AU - Barcellos-Hoff, Mary Helen

AU - Bhardwaj, Nina

AU - Chan Wah Hak, Charleen

AU - Fiorentino, Alba

AU - Guha, Chandan

AU - Guzman, Monica L.

AU - Harrington, Kevin

AU - Herrera, Fernanda G.

AU - Honeychurch, Jamie

AU - Hong, Theodore

AU - Iturri, Lorea

AU - Jaffee, Elisabeth

AU - Karam, Sana D.

AU - Knott, Simon R.V.

AU - Koumenis, Constantinos

AU - Lyden, David

AU - Marciscano, Ariel E.

AU - Melcher, Alan

AU - Mondini, Michele

AU - Mondino, Anna

AU - Morris, Zachary S.

AU - Pitroda, Sean

AU - Quezada, Sergio A.

AU - Santambrogio, Laura

AU - Shiao, Stephen

AU - Stagg, John

AU - Telarovic, Irma

AU - Timmerman, Robert

AU - Vozenin, Marie Catherine

AU - Weichselbaum, Ralph

AU - Welsh, James

AU - Wilkins, Anna

AU - Xu, Chris

AU - Zappasodi, Roberta

AU - Zou, Weiping

AU - Bobard, Alexandre

AU - Demaria, Sandra

AU - Galluzzi, Lorenzo

AU - Deutsch, Eric

AU - Formenti, Silvia C.

PY - 2023/1/1

Y1 - 2023/1/1

N2 - Focal radiation therapy (RT) has attracted considerable attention as a combinatorial partner for immunotherapy (IT), largely reflecting a well-defined, predictable safety profile and at least some potential for immunostimulation. However, only a few RT-IT combinations have been tested successfully in patients with cancer, highlighting the urgent need for an improved understanding of the interaction between RT and IT in both preclinical and clinical scenarios. Every year since 2016, ImmunoRad gathers experts working at the interface between RT and IT to provide a forum for education and discussion, with the ultimate goal of fostering progress in the field at both preclinical and clinical levels. Here, we summarize the key concepts and findings presented at the Sixth Annual ImmunoRad conference.

AB - Focal radiation therapy (RT) has attracted considerable attention as a combinatorial partner for immunotherapy (IT), largely reflecting a well-defined, predictable safety profile and at least some potential for immunostimulation. However, only a few RT-IT combinations have been tested successfully in patients with cancer, highlighting the urgent need for an improved understanding of the interaction between RT and IT in both preclinical and clinical scenarios. Every year since 2016, ImmunoRad gathers experts working at the interface between RT and IT to provide a forum for education and discussion, with the ultimate goal of fostering progress in the field at both preclinical and clinical levels. Here, we summarize the key concepts and findings presented at the Sixth Annual ImmunoRad conference.

KW - FLASH radiotherapy

KW - dose and fractionation

KW - immune checkpoint inhibitors

KW - immunomodulators

KW - lymph node sparing

KW - tumor-associated macrophages

UR - http://www.scopus.com/inward/record.url?scp=85162911591&partnerID=8YFLogxK

U2 - 10.1080/2162402X.2023.2222560

DO - 10.1080/2162402X.2023.2222560

M3 - Review article

AN - SCOPUS:85162911591

SN - 2162-4011

VL - 12

JO - OncoImmunology

JF - OncoImmunology

IS - 1

M1 - 2222560

ER -